Bioneer Corporation (064550) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioneer Corporation (064550) has a cash flow conversion efficiency ratio of 0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩860.54 Million ≈ $583.18K USD) by net assets (₩229.21 Billion ≈ $155.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Bioneer Corporation to measure how many days the company can operate on defensive assets alone.
Bioneer Corporation - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Bioneer Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bioneer Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioneer Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Impact Develop
RO:IMP
|
-0.002x |
|
I-Berhad
KLSE:4251
|
0.032x |
|
Wam Active Ltd
AU:WAA
|
0.010x |
|
BRIG.M3 EUROP.ACQ.A-0001
F:KN2
|
N/A |
|
N. Varveris-Moda Bagno S.A
AT:MODA
|
0.043x |
|
Bank Qnb Indonesia Tbk
JK:BKSW
|
-0.021x |
|
Garuda Metalindo Tbk PT
JK:BOLT
|
-0.092x |
|
Greenheart Gold Inc.
V:GHRT
|
-0.089x |
Annual Cash Flow Conversion Efficiency for Bioneer Corporation (2014–2024)
The table below shows the annual cash flow conversion efficiency of Bioneer Corporation from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 064550 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩226.89 Billion ≈ $153.76 Million |
₩-13.48 Billion ≈ $-9.13 Million |
-0.059x | -437.31% |
| 2023-12-31 | ₩234.88 Billion ≈ $159.17 Million |
₩4.14 Billion ≈ $2.80 Million |
0.018x | -52.80% |
| 2022-12-31 | ₩236.00 Billion ≈ $159.94 Million |
₩8.81 Billion ≈ $5.97 Million |
0.037x | -85.75% |
| 2021-12-31 | ₩203.05 Billion ≈ $137.60 Million |
₩53.17 Billion ≈ $36.04 Million |
0.262x | -60.16% |
| 2020-12-31 | ₩145.61 Billion ≈ $98.68 Million |
₩95.71 Billion ≈ $64.86 Million |
0.657x | +459.95% |
| 2019-12-31 | ₩30.61 Billion ≈ $20.74 Million |
₩-5.59 Billion ≈ $-3.79 Million |
-0.183x | +12.25% |
| 2018-12-31 | ₩38.99 Billion ≈ $26.42 Million |
₩-8.11 Billion ≈ $-5.50 Million |
-0.208x | -44.77% |
| 2017-12-31 | ₩27.15 Billion ≈ $18.40 Million |
₩-3.90 Billion ≈ $-2.64 Million |
-0.144x | +8.26% |
| 2016-12-31 | ₩26.11 Billion ≈ $17.70 Million |
₩-4.09 Billion ≈ $-2.77 Million |
-0.157x | -1427.23% |
| 2015-12-31 | ₩34.53 Billion ≈ $23.40 Million |
₩407.68 Million ≈ $276.28K |
0.012x | +108.26% |
| 2014-12-31 | ₩30.20 Billion ≈ $20.47 Million |
₩-4.31 Billion ≈ $-2.92 Million |
-0.143x | -- |
About Bioneer Corporation
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analys… Read more